Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study
- 494 Downloads
Randomized trials have demonstrated the efficacy of radiation and tamoxifen in reducing risk of second events after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS), but the comparative effectiveness of mastectomy, BCS, and adjuvant treatments have not been established in community practice. We examined disease-free survival (DFS) among 1,676 DCIS cases diagnosed during 1995–2006 in the population-based Wisconsin In Situ Cohort study. Information on patient and tumor characteristics, treatments, and second breast cancer events were collected via a comprehensive review of data from patient interviews, the statewide cancer registry, and pathology reports. Breast cancer DFS was evaluated according to treatment while adjusting for patient and tumor characteristics. After an average of 7.1 years of follow-up, 143 second breast cancer events occurred. Overall 5-year DFS was similar among women treated with ipsilateral mastectomy (95.6 %; 95 % CI 93.5–97.0) compared to women treated with BCS and radiation (94.8 %; 95 % CI 92.8–96.1), though women receiving BCS without radiation experienced poorer overall DFS (87.0 %; 95 % CI 80.6–91.5). Women treated with tamoxifen in addition to BCS and radiation had a similar risk of a second breast event, although the hazard ratio (HR) suggested a potential benefit (0.70, 95% CI 0.41-1.19). Women treated with BCS, radiation, and tamoxifen had comparable risk of a second event as those treated with ipsilateral mastectomy (HR = 1.20; 95 % CI 0.71–2.02). In this population-based sample, the use of BCS with radiation and tamoxifen resulted in high DFS rates comparable to those achieved by ipsilateral mastectomy.
KeywordsDuctal carcinoma in situ Disease-free survival Breast cancer Treatment
National Cancer Institute (U54 CA163303, R01 CA67264, R01 CA47147, P30 CA14520); Department of Defense Breast Cancer Research Program (BC102357); American Society of Preventive Oncology sponsored by Susan G. Komen for the Cure and the Prevent Cancer Foundation (PCF-0596). We would like to thank Drs. Andreas Friedl, Kathleen Egan, Linda Titus, Hazel Nichols, and Shaneda Warren Andersen, along with Kathy Peck, Julie McGregor, Laura Stephenson and the Wisconsin Cancer Reporting System.
The authors declare that they have no conflict of interest.
- 1.Silverstein MJ, Baril NB (2002) In situ carcinoma of the breast. In: Donegan WL, Spratt JS (eds) Cancer of the breast, 5th edn. Saunders, PhiladelphiaGoogle Scholar
- 3.Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H et al (2012) SEER cancer statistics review, 1975–2009. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012
- 4.American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society, Inc., AtlantaGoogle Scholar
- 6.Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA et al (2010) National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ September 22–24, 2009. J Natl Cancer Inst 102(3):161–169PubMedCrossRefGoogle Scholar
- 10.Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12(1):21–29PubMedCrossRefGoogle Scholar
- 12.Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853: a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387PubMedCrossRefGoogle Scholar
- 13.Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S (2008) Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 26(8):1247–1252PubMedCrossRefGoogle Scholar
- 19.Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E (1995) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 75(6):1310–1319PubMedCrossRefGoogle Scholar
- 20.Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16(2):441–452PubMedGoogle Scholar
- 22.Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993–2000PubMedCrossRefGoogle Scholar
- 29.Habel LA, Achacoso NS, Haque R, Nekhlyudov L, Fletcher SW, Schnitt SJ, Collins LC, Geiger AM, Puligandla B, Acton L et al (2009) Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res 11(6):R85PubMedCentralPubMedCrossRefGoogle Scholar